Articles tagged with Hormone Therapy
A new Women's Health Initiative report shows hormone therapy is associated with a higher incidence of invasive breast cancer and increased risk of death from breast cancer. The study found that postmenopausal women taking estrogen plus progestin had more advanced cancers with lymph node involvement, leading to poorer prognosis
A new study found that estrogen replacement therapy significantly speeds up ovarian cancer growth and increases the likelihood of cancer metastasizing to the lymph nodes. Researchers discovered estrogen-regulated genes specific to ER+ ovarian cancer that can be targeted with new anti-estrogen therapies.
A study published in the JAMA Network found that hormone therapy use by postmenopausal women is associated with an increased incidence of invasive breast cancers, particularly those with positive lymph nodes. The study also showed a higher risk of deaths attributable to breast cancer among women who received combined hormone therapy.
A study published in Archives of Internal Medicine found that hormone therapy after menopause increases the risk of developing kidney stones by approximately 20 percent. The research calls into question the long-held belief that estrogen protects women from the disease, and clinicians need to consider the risks and benefits of hormone ...
Postmenopausal women taking estrogen therapy are at a higher risk of developing kidney stones, according to a study. The research found a significant increase in kidney stone development, with a fivefold greater risk in women with a history of kidney stones.
A study published in Cancer found that racial disparities in breast cancer care persist, even after accounting for patients' insurance and socioeconomic status. Black and Hispanic women are less likely to receive recommended treatments compared to white women.
The International Menopause Society launches new treatment recommendations for postmenopausal vaginal atrophy, a condition affecting up to half of women after menopause. The guidelines aim to improve awareness and understanding of VA among women, who often live with the condition unnecessarily due to fear of hormone replacement therapy.
The addition of immunotherapy to standard therapy increases the percentage of children with high-risk neuroblastoma who are alive and free of disease progression after two years. The new regimen, which targets a substance on tumor cells called GD2, presents a clear paradigm shift in treating this cancer.
Researchers identified insulin-like growth factor 1 receptor (IGF-1R) overexpression in 25% of triple-negative breast cancers, correlated with gene amplification. IGF-1R blockade has been successful in sarcomas, and targeting this receptor may offer new therapeutic options for triple-negative breast cancer.
A new study published in the Journal of Sexual Medicine found that 70% of women are facing sexual function problems approximately two years post-diagnosis. The study suggests that specific treatments for breast cancer, such as aromatase inhibitors, can exacerbate menopausal symptoms leading to sexual problems.
A study analyzing Canadian data shows a decline in breast cancer incidence among postmenopausal women as hormone therapy prescriptions fell. The decline, which coincided with a drop in hormone replacement therapy use, suggests that HRT may be linked to an increased risk of breast cancer.
A new study found that higher baseline leptin and lower ghrelin plasma levels before dieting may predict weight regain in individuals. The research suggests that personalized weight-loss programs targeting appetite hormones could improve long-term success rates.
The Endocrine Society recommends that every newborn be screened for CAH, and positive results be followed up with confirmatory tests. The guideline also outlines treatment recommendations, including minimizing glucocorticoid dosage and considering patients' quality of life.
A study published by the American Physiological Society suggests that as body mass index (BMI) increases, so do platelet reactivity and thrombogenic microvesicles, contributing to cardiovascular disease. Higher BMI groups also showed increased traditional cardiovascular risk factors such as blood pressure and triglycerides.
A new analysis found that prostate cancer treatment choices significantly impact long-term care costs. Watchful waiting had the lowest initial and five-year total costs, while hormonal therapy plus radiation and surgery were associated with higher costs.
Researchers compared four progestins and found that N-EL and N-One strongly inhibited tumor development, while MPA promoted it. Progestins like N-EL and N-One may have potential as preventive agents in women with no breast disease or family history.
A new study suggests that oral contraceptives and hormone replacement therapy may reduce the incidence of brain aneurysms in women. The study, conducted at Rush University Medical Center, found strong similarities between women with unruptured and ruptured aneurysms, including lower estrogen levels.
UT Southwestern researchers found blocking a specific enzyme step can halt tumor growth. The study suggests this approach may provide new therapy options for patients with end-stage prostate cancer, which has limited treatment choices.
Research reveals soy phytoestrogens reduce weight gain and increase energy expenditure in post-menopausal rats, highlighting potential natural treatment for obesity. Further human studies are needed to confirm the long-term effects of a soy-rich diet on food intake.
A study found that women with a genetic variation in their hormone receptor are more likely to have a poor response to FSH during fertility treatment. The abnormal receptor impairs the function of normal receptors, resulting in fewer oocytes produced.
A new study found that nearly 49% of women with early-stage breast cancer did not complete their full hormone therapy regimen. Younger women were more likely to discontinue treatment. The study highlights the need for better understanding and interventions to reduce treatment non-compliance.
Menopausal hormone therapy may offer significant benefits to some women, particularly those starting treatment a short time after menopause. The Endocrine Society's new statement suggests that MHT can lead to a 30-40% decrease in mortality and a 90% reduction of menopausal symptoms.
A new study reveals that oral micronized progesterone relieves hot flashes and night sweats in postmenopausal women, with a 56% improvement rate. The natural hormone form offers an effective alternative to estrogen for those who cannot or prefer not to use it.
A large UK study found that genetic variations associated with an increased risk of breast cancer do not interact with environmental factors such as hormone replacement therapy, age at first birth, or obesity. The study's authors conclude that genetic and environmental risks for breast cancer are independent.
Researchers found thymoquinone induces oxidative stress in prostate cancer cells, leading to increased cell death and decreased tumor growth. The study suggests a new potential treatment option for highly aggressive prostate cancers.
A nationwide study confirms the benefit of estrogen-lowering drugs before surgery for breast cancer patients. The treatment increased the likelihood that women could undergo breast-conservation surgery instead of mastectomy. After 16-week aromatase inhibitor therapy, 82% of women had successful breast-conservation surgery.
Researchers from Georgetown University Medical Center identify a potential new combination therapy to increase or 'rescue' sensitivity to fulvestrant in ER+ breast cancers. The study found that the cytokine IFNγ appears to increase IRF1 expression, leading to increased apoptosis of cancer cells.
Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, a debilitating disease caused by steroid use. Injecting ACTH significantly reduced bone death in rabbits with osteonecrosis, promoting increased blood flow to bone cells and preventing cell death.
Researchers from Georgetown University Medical Center are studying multiple ways to address treatment-resistant breast cancers. A third approach involves triggering vulnerable cells to respond to existing treatments, while another study focuses on targeting orphan nuclear receptors to prevent resistance.
The European Association of Urology (EAU) has launched new and updated clinical guidelines for urological conditions, including muscle-invasive and metastatic bladder cancer and prostate cancer. The guidelines provide evidence-based recommendations on diagnosis, staging, treatment options, and follow-up care.
A study published in The Lancet Oncology found that men with prostate cancer are at increased risk of potentially life-threatening blood clots. Patients receiving endocrine therapy had the highest risk, especially younger men and those with advanced disease.
An international expert group recommends individualized treatment for patients with type 2 diabetes, citing the need to address underlying physiological and genetic differences. The recommendations aim to improve glycemic control, minimize risk, and reduce diabetes complications by tailoring therapies to specific patient subgroups.
Researchers discover how breast cancer cells become resistant to hormone-dependent treatments like tamoxifen by activating a specific biochemical cascade. The study reveals the permanent stimulation of cyclic AMP in cells refractory to therapy, providing key answers to understanding resistance.
Researchers found that hormone replacement therapy in joint fluid may be beneficial for treating late-stage human osteoarthritis by regenerating damaged cartilage tissue. Estrogen and testosterone were shown to influence the expression of genes in chondrogenic progenitor cells, which are present in arthritic tissue.
A study found Raloxifene improves psychosis symptoms and enhances memory in postmenopausal women with schizophrenia. The therapy may revolutionize treatment options for women suffering from the condition.
Magnetic resonance-guided focal therapy offers a new treatment choice for patients with recurrent prostate cancer, providing an alternative to radiation therapy and hormone manipulation. The procedure involves tailored treatment modality and duration based on lesion size and location, preserving sexual and urinary function.
A study found that prostate cancer treatment options differ based on the type of specialist consulted. Men who see a radiation oncologist are more likely to receive radiation therapy, while those who consult with a urologist with or without a medical oncologist are treated more frequently with hormone therapy, watchful waiting, or radi...
Monash University scientists have identified a new way to treat castrate-resistant prostate cancer cells using estrogen receptors. The study shows that activating these receptors can cause cell death in patients with advanced prostate cancer.
Recent research highlights the existence of multiple placebo effects, influenced by psychological and neurobiological factors. Placebo effects can be robust in both laboratory and clinical settings, and can even enhance the efficacy of treatments.
A recent study published in Cancer journal by HealthCore confirms disparities in breast cancer treatment between African-American and white women. White women were more likely to receive anti-estrogen therapy compared to African-American women, despite both groups having similar cancer stages. The study highlights the need for improved...
New analyses confirm that combination hormone therapy increases the risk of heart disease in healthy postmenopausal women, particularly those who begin therapy within 10 years of menopause. The risk is more pronounced among women who start therapy 10 years or more after menopause.
Researchers identified a gene variant that affects mice's response to natural hormone fluctuations, leading to increased anxiety and impaired memory. The study suggests the gene may play a role in premenstrual dysphoric disorder (PMDD) and other menstrual cycle-related disorders.
A large-scale study found that estrogen-only hormone replacement therapy (HRT) may increase the risk of developing asthma after menopause. Women who used estrogen-only HRT were 21% more likely to develop asthma than those who never used HRT, with a significant increased risk among non-smokers and those with previous allergies.
A Tel Aviv University study found that restoring normal estrogen levels can alleviate schizophrenia-like behavior in female rats. The researchers also discovered that estrogen increases the effectiveness of anti-psychotic drugs, providing potential hope for treating psychosis in women vulnerable to schizophrenia.
Researchers found prescribed opioids associated with significant overdose risk. Leptin therapy holds promise for long-term weight loss. Atrial fibrillation risk is lower with certain antihypertensives, while higher statin doses may not always prevent coronary artery disease.
Researchers at University of California, Berkeley have discovered a new human reproductive hormone called gonadotropin inhibitory hormone (GnIH), which has the opposite effect from gonadotropin releasing hormone. GnIH may lead to the development of novel contraceptives and treatments for cancer or other diseases.
Researchers suggest progesterone as a viable treatment option for traumatic brain injuries due to its ability to protect damaged cells and reduce swelling. The hormone has been shown to improve behavioral outcomes and protect neurons after injury.
A recent study found that black women with hormone receptor-positive breast cancer have worse disease-free and overall survival rates than women of other races. This disparity persists even after controlling for other factors such as medical care and comorbidities.
A new study published in the Journal of the National Cancer Institute found that treatment with gonadotropin-releasing hormone agonists increases the risk of incident diabetes among men of all ages diagnosed with local or regional prostate cancer. The study also found an increased risk of cardiovascular disease, including coronary hear...
A randomised trial found that medroxyprogesterone acetate is significantly more effective than venlafaxine at reducing hot flushes in men treated with androgen suppression therapy. Cyproterone acetate was also effective, but medroxyprogesterone is recommended as the standard treatment due to its fewer side effects.
Dr. Donald F. Steiner has made significant contributions to the understanding of insulin secretion and related disorders through his research on proinsulin and C-peptide measurement. His work has led to major improvements in therapeutic insulin development, diagnosis of pancreatic tumors, and islet transplants.
Women with a history of preeclampsia may be at increased risk for reduced thyroid functioning, according to researchers. The study found that women who developed preeclampsia during pregnancy had higher levels of thyroid-stimulating hormone (TSH) and were more likely to have hypothyroidism later in life.
Researchers at Johns Hopkins Medicine found that migraine headaches are associated with more than two-fold higher chances of ischemic stroke. Women with migraines have a particularly high risk, with a 2.9 times higher risk compared to men.
A large national study on testosterone's effectiveness will be conducted at LA BioMed, focusing on its impact on anemia, cardiovascular disease, and other health conditions in older men with low testosterone levels. The Testosterone Trial will involve 800 men across 12 sites, including LA BioMed, to evaluate the treatment's benefits.
Researchers Darío Acuña-Castroviejo and Germaine Escames found that melatonin is an effective sleep regulator, regulating the biological clock and synchronizing the body's circadian rhythms. Taking melatonin at specific hours can correct chronobiological alterations of the cycle sleep/wakefulness.
A phase III study found that short-term hormone therapy added to radiation treatment significantly increases survival in medium-risk prostate cancer patients by 51% compared to those receiving radiation alone. In contrast, low-risk patients showed no significant benefit from this combination.
Researchers have identified a molecular mechanism underlying DES-induced male infertility in mice, which may be linked to increased incidence of human reproductive disorders. The study found that neonatal exposure to DES disrupts the protein NR0B2, leading to reduced fertility and protected males against negative effects.
A phase III study found that short-term hormone therapy given prior to and during intermediate dose radiation treatment significantly increases the chance of living longer (51 percent) compared to those who receive radiation alone. The benefit appeared to be greatest for men at medium-risk for disease failure.
Researchers found proton therapy to have excellent early tolerance with minimal urinary and rectal toxicity. The study showed a low rate of Grade 3 genitourinary and gastrointestinal side effects, with the most common being minor rectal bleeding.
The American College of Physicians recommends initiating therapy with a PDE-5 inhibitor in men with ED unless there's a contraindication. Treatment with PDE-5 inhibitors results in statistically significant improvements in sexual intercourse and erectile function, regardless of cause or baseline severity.